Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT04896073Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of minnelide in adenosquamous carcinoma of the pancreas (ASCP), sponsored by National Cancer Institute. Primary endpoint: Disease Control Rate at 16 weeks. Started Mar 2022; status: completed.
02
Drugs
minnelide
03
Conditions
adenosquamous carcinoma of the pancreas (ASCP)
Beyond the preview
Go deeper on NCT04896073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896073.